Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Challenges of tuberculosis control

Sally Murray
CMAJ January 03, 2006 174 (1) 33-34; DOI: https://doi.org/10.1503/cmaj.051504
Sally Murray
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1.

Mycobacterium tuberculosis infects a third of the world's population and kills 2 million people each year: there is a new infection every second. Most cases currently are located in southeast Asia, with one-third of new cases arising in this region each year (Table 1, Fig. 1). Rates of tuberculosis (TB) are also increasing rapidly in Africa, in parallel with the HIV/AIDS epidemic.

The continuing challenges of TB control can be distributed into 5 key areas: inadequate diagnostics and treatment; the need for expansion of the World Health Organization (WHO) Directly Observed Therapy, short course (DOTS) program; multidrug-resistant tuberculosis (MDRTB); and HIV coinfection.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Fig. 1: Worldwide notification rates for tuberculosis for 2003. Source: the World Health Organization (WHO).1

The diagnostic tools in use for TB are old and often ineffective. Sputum-smear microscopy, which was developed in 1882, does not detect extrapulmonary or smear-negative TB, and is less effective in children and people infected with HIV, whose smear results are often negative.1 Most laboratories also lack the facilities to identify MDRTB.2

Drugs currently being used to treat TB have also been on the market for many years: isoniazid was first used in 1952, rifampicin in 1965, and ethambutol in 1968.1 The chief problem with these drugs is the need for prolonged treatment: regimens are currently recommended for 6–9 months, and failure to adhere to long treatment courses results in resistant strains and relapse. To facilitate compliance with these onerous treatments, WHO introduced the DOTS program in 1991, which includes 5 essential components: case detection by sputum-smear microscopy, government commitment to TB control, regular supply of drugs, supervised treatment, and reports on the progress of the health system.

WHO has helped more than 180 countries implement DOTS. Despite its successes, 14 years of data have revealed the limitations of the program: globally, only 45% of the estimated cases of active TB were treated under DOTS in 2003.3 This is partly because DOTS was originally aimed at patients whose smears test positive; those with extrapulmonary or smear-negative TB (i.e., half of patients) miss inclusion in treatment programs. Although DOTS has now been expanded to include some of these people,3 “low-priority” patients such as those with chronic TB or MDRTB still fall outside the program's recommendations for treatment priority.1

Inconsistent or partial treatment has resulted in TB that is resistant to isoniazid and rifampicin. MDRTB accounts about 1% of new TB cases.3 It is a particular problem in countries of the former Soviet Union, owing to the breakdown in health system infrastructure and subsequent incomplete or inadequate treatments. Although MDRTB is generally treatable, the drugs required must be taken for up to 2 years and are considerably more expensive and toxic.3

Finally, HIV infection compounds the problems of accurate diagnosis as well as adequate treatment. TB causes more rapid deterioration of the immune systems of people with HIV or AIDS, and they are 100 times more likely to have active TB during their lifetime than people who are HIV-negative.2 People with advanced HIV infection can have active TB that is smear-negative or without typical chest radiography features, which means that coexistent TB infections remain untreated.

The relapse rates associated with the use of some anti-TB regimens are increased among HIV-positive people. Concomitant use of antiretroviral drugs has clinically significant toxicity and drug interactions, and the optimum timing for antiretroviral therapy in patients with TB is still unknown.2,4 Furthermore, after starting antiretroviral drugs patients may experience an immune reconstitution syndrome that mimics many aspects of TB infection, which makes the clinical picture in coinfected patients unclear.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Box 1.

To address the challenges facing TB control, various global groups are advocating for and supporting research and development in this area (Box 1). A recent new development is the whole-blood interferon γ assay, which detects interferon in response to TB challenge, and is currently being validated in the field.2,4 Diarylquinolone is an encouraging new treatment initiative that appears to be highly active against TB (including MDRTB) and requires shorter periods of treatment. Trials of vaccines are also underway, and the merits of treating latent TB are being debated for people who are recently infected or are at increased risk of progression to TB (e.g., people who test positive for HIV) in both developing and developed countries.2,4 The use of any new measures will need to be considered in their global context — one often plagued by poverty, overcrowding and health systems that are short on funding and trained staff.

Figure

Figure. Alice Neel. T.B. Harlem, 1940. Oil on canvas. Photo by: National Museum of Women in the Arts, Washington, DC

REFERENCES

  1. 1.↵
    Médecins Sans Frontières. Running out of breath: TB care in the 21st century. Geneva: the organization; 2005. Available: www.accessmed-msf.org/documents/tbreportseptember2004.pdf (accessed 2005 Nov 24).
  2. 2.↵
    Frothingham R, Stout JE, Dukes Hamilton C. Current issues in global tuberculosis control. Int J Infect Dis 2005;9:297-311.
    OpenUrlCrossRefPubMed
  3. 3.↵
    World Health Organization (WHO). Global tuberculosis control: surveillance, planning and financing. Geneva: WHO; 2005.
  4. 4.↵
    Blumberg HM, Leonard MK, Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA 2005;293:2776-84.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 174 (1)
CMAJ
Vol. 174, Issue 1
3 Jan 2006
  • Table of Contents
  • Index by author
  • Canadian Adverse Reaction Newsletter (117-124)

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Challenges of tuberculosis control
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Challenges of tuberculosis control
Sally Murray
CMAJ Jan 2006, 174 (1) 33-34; DOI: 10.1503/cmaj.051504

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Challenges of tuberculosis control
Sally Murray
CMAJ Jan 2006, 174 (1) 33-34; DOI: 10.1503/cmaj.051504
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • REFERENCES
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights of this issue • Dans ce numéro
  • A collective problem of caring
  • PubMed
  • Google Scholar

Cited By...

  • Use of Hydrogen Peroxide Vapor for Deactivation of Mycobacterium tuberculosis in a Biological Safety Cabinet and a Room
  • Corrections
  • Google Scholar

More in this TOC Section

  • Management of γ-hydroxybutyrate intoxication and withdrawal
  • Tuberculous monoarthritis of the knee joint
  • Vulvar condyloma lata as a first presentation of syphilis
Show more Practice

Similar Articles

Collections

  • Topics
    • Global health
    • Infectious diseases

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire